Strata Critical Medical (SRTA) Revenue (2020 - 2026)

Strata Critical Medical (SRTA) has reported Revenue for 7 consecutive years, with $67.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue rose 87.45% year-over-year to $67.4 million; the TTM figure through Mar 2026 stood at $254.3 million (up 44.19% YoY), while the FY2025 annual figure was $197.1 million, up 34.28% from the prior year.
• Revenue rose to $67.4 million in Q1 2026 per SRTA's latest filing, from $66.8 million in the prior quarter.
• Across five years, Revenue topped out at $71.4 million in Q3 2023 and bottomed at $26.6 million in Q1 2022.
• Historically, Revenue has averaged $53.1 million across 5 years, with a median of $51.5 million in 2024.
• Annual changes were most pronounced in 2022 — Revenue soared 187.18% — and 2024, when it slumped 49.52%.
• Strata Critical Medical's Revenue stood at $62.3 million in 2022, then slipped by 23.75% to $47.5 million in 2023, then dropped by 23.36% to $36.4 million in 2024, then jumped by 83.54% to $66.8 million in 2025, then grew by 0.89% to $67.4 million in 2026.
• Business Quant data shows SRTA's Revenue at $67.4 million in Q1 2026, $66.8 million in Q4 2025, and $49.3 million in Q3 2025.